Incidence of ESBL producers amongst Gram-negative bacilli isolated from intra-abdominal infections across India (Based on SMART study, 2007 data)

Journal of Association of Physicians of India

Volumn 59, Issue 5, 2011, Pages

  Chaudhuri, B N ^a   Rodrigues, C ^b   Balaji, V ^c   Iyer, R ^d   Sekar, U ^e   Wattal, Chand ^f   Chitnis, D S ^g   Dhole, T N ^h   Joshi, Sangeeta ⁱ  

^a AMRI HOSPITALS   (India)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

^c CHRISTIAN MEDICAL COLLEGE   (India)

^d Global Hospital   (India)

^e SRI RAMACHANDRA UNIVERSITY   (India)

^f SIR GANGA RAM HOSPITAL   (India)

^g CHOITHRAM HOSPITAL AND RESEARCH CENTRE   (India)

^h SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ MANIPAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE;

ABDOMEN; ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; COMMUNICABLE DISEASE; CROSS INFECTION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INCIDENCE; INDIA; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ABDOMEN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; INDIA; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 79956199914     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Spencer RC, Bauernfeind A, Garcia-Rodriquez J, et al. Surveillance of the current resistance of nosocomial pathogens to antibacterials. Clin. Microbiol Infect 1997;3(Suppl 1):S21-S35.
2. Sahm, DF, Marsilio, MK & Piazza, G (1999). Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with The Surveillance Network database USA. Clinical Infectious Diseases 1996;29:259-63.
3. Jones, RN The emergent need for Basic Research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance. Diagnostic Microbiology and Infectious Diseases 1996;25:153-61.
4. Livermore D, Carter M, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agent Chemother 2001;45:1860-7.
5. Fuchs PC, Barry AL, Brown SD. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother 1999;43:703-6.
6. Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell KL. Comparative in vitro activities ertapenem (MK-0826) against 1,001 anaerobes isolated from human intra-abdominal infections. Antimicrob Agent Chemother 2000;44:2389-94.
7. Wexler HM, Molitoris D, Finegold SM. In vitro activities of MK-826 (L-749, 345) against 363 strains of anaerobic bacteria. Antimicrob Agents Chemother 2000;44:2222-4.
8. Pankuch GA, Davies TA, Jacobs MR, Appelbaum PC. Antipneumococcal activity of ertapenem (MK-0826) compared to those of other agents. Antimicrob Agent Chemother 2002;46:42-46.
9. Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749, 345) against broad-spectrum β-lactamase and extended-spectrum β-lactamase producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999;43:1170-6.
10. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749, 345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents and Chemother 1997;41:1830-1.
11. Solomkin J, Choe K, Christou N, et al. Results of a prospective, randomized, triple-blind study of ertapenem vs. piperacillin/ tazobactam for complicated intra-abdominal infection [Abstract]. 11th European Congress of Clinical Microbiology and Infectious Diseases 2001 Apr 1-4; Istanbul, Turkey; 2001;1460.
12. Graham D, Lucasti C, Malafaia O, et al. Ertapenem once daily versus piperacillin/tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind study. Clinical Infectious Diseases 2002;11:1460-1468.
13. Roy S, Higareda I, Angel-Muller E, et al. Results of a phase III randomized, double-blind study of ertapenem (ETP) vs piperacillin/ tazobactam (P/T) for acute pelvic infection (Inf) in women [Abstract]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 23; Chicago, Illinois; 2001: L-888.
14. Tomera, Kevin M, et al. Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind, multicenter study. Antimicrob Agents Chemother 2002;46:2895-2900.
15. Guillermo O, Caballero-Lopez J, Friedland I, et al. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clinical Infectious Diseases 2002;34:1076-83.
16. Hawser SP, Bouchillon SK, Hoban DJ, etal. Emergence of High Levels of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli in the Asia-Pacific Region: Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program, 2007. Antimicrob Agents Chemother 2009;53:3280-3284.